Name: Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications (Video) | JoVE Journal
Uploaded: 2025-09-02T13:00:00.000+00:00
Duration: 6 min 42 s
Description: Learn optimized breast biopsy and mastectomy sample collection for biobanking and personalized medicine using ultrasound-guided techniques. This protocol enables high-quality RNA sequencing and organoid culture for cancer research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This research is funded by the Department of Science and Technology, Philippine Council for Health Research and Development (DOST-PCHRD), and conducted in collaboration with the Philippine Genome Center (PGC) and University of the Philippines Diliman - Institute of Biology (UPD-IB). The authors would also like to thank Mr. Lech Havel Tizon, Mr. Conrad Chong, and Ms. Susan Valibia for their assistance in optimizing this protocol,&#160;as well as the pathology residents&#160;who contributed to the filming of this protocol, Dr. Clarisse Veronica Mirhan and Dr. Patricia Franco.

This is a prospective, observational study with a collection of de-identified biospecimens (tumor and normal breast tissue) and clinicopathologic, treatment, and outcome data from 100 Filipino breast cancer patients of various stages. This is a collaborative work between the Philippine General Hospital (PGH), the Philippine Genome Center (PGC), and the Institute of Biology (IB) of the University of the Philippines Diliman, each with designated tasks. The protocol was&#160;registered in the Research Grants Administration Office (RGAO-2020-0933), and reviewed and approved by the University of the Philippines Manila Research Ethics Board (UPMREB) for implementation under ethics clearance number UPMREB 2020-822-01. All laboratories used adhere to the biosafety guidelines of each institution. Recruiting patients from PGH ensured the variance and representation in terms of clinicopathologic factors, ethnicity, and environmental exposures. A standard operating procedure (SOP) developed and validated in previous projects was utilized as the framework for the acquisition, collection, transportation, and other logistical arrangements related to the samples.
NOTE: See Figure 1 - Diagrammatic workflow of the protocol for the summary of the protocol workflow and the roles of each institution involved in the study.
1. Pre-breast sample collection procedure
<ol>
	<li>Identify and screen the eligible patients for study inclusion during a clinic consult or preoperative conference.
	<ol>
		<li>Inclusion criteria for cancer patients
		<ol>
			<li>Include Filipino, female, aged 19-75 years old diagnosed with Stage 1, 2, and 3 breast cancer, and Filipino females aged 19-70 years old diagnosed with Stage 3B and 4 breast cancer.</li>
			<li>Include clinically suspected or pathologically diagnosed cases of invasive breast cancer of any stage.</li>
			<li>Include patients who will undergo surgical treatment (modified radical mastectomy or radical mastectomy) either upfront (Clinical Stage I or II) or post-neoadjuvant chemotherapy (Stage IIIB, IIIC). Stage IIIA patients may undergo either upfront surgery or neoadjuvant therapy as per the physician&#39;s recommendations. For Stage IV patients, those willing to undergo core needle biopsy of the breast tumor and adjacent normal tissue. Stage IV breast cancer patients will not undergo surgical treatment.</li>
			<li>Include Stage III breast cancer patients who have undergone neoadjuvant therapy prior to recruitment, and there is a complete medical and clinical treatment response record.</li>
			<li>Include patients who can understand and sign informed consent.</li>
		</ol>
		</li>
		<li>Exclusion criteria for cancer patients
		<ol>
			<li>Exclude patients who have prior or concurrent malignancy, including prior diagnosis of breast cancer.</li>
			<li>Exclude patients with bilateral breast cancer.</li>
			<li>Exclude patients who underwent prior neoadjuvant radiotherapy or hormonal therapy.</li>
			<li>Exclude patients who underwent prior core or incisional biopsy where there is no consent to repeat biopsy procedure for those patients who will undergo neoadjuvant chemotherapy (since no pre-chemotherapy fresh tumor specimen can be obtained)</li>
			<li>Exclude patients who underwent prior excisional biopsy with no residual tumor.</li>
			<li>Exclude patients with comorbidities precluding surgical management or neoadjuvant chemotherapy.</li>
		</ol>
		</li>
		<li>Withdrawal criteria
		<ol>
			<li>Inform participants that they can withdraw anytime for safety or other concerns without affecting their medical care. This non-interventional study will not impact the choice of treatment for participants.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Secure consent from the patient and fill out the data collection form. 
	NOTE: The assigned fellow-in-charge (FIC) or the consultant, together with the university research associate (URA), secures the consent.</li>
	<li>Obtain and verify the patient&#39;s schedule for the core needle biopsy procedure after confirming their participation in the study.</li>
	<li>Conduct procedures in compliance with the guidelines set and approved by the Ethics Board Committee and Biosafety Committee of the institution.</li>
</ol>
2. Breast biopsy sample collection procedure
NOTE: See Figure 2 for the detailed workflow of the core needlebreast biopsy procedure for stage III and IV patients, showing the distribution of samples for each procedure.
<ol>
	<li>Pre-label tubes before specimen collection as GB, meaning Genomics - Breast (the study the specimen is under), xxx which is the participant number and can range from 001 to 100, or more, and the letters A, C and D. The following are the letter codes to be used in labeling the tubes: 
	A - means core needle biopsy, tumor tissue, for sending to PGC 
	C - means core needle biopsy, tumor tissue, for biobanking 
	&#8203;D - means core needle biopsy, normal tissue
	<ol>
		<li>Assign the samples submitted for sequencing with the laboratory&#39;s label: &#34;BC&#34; and two two-digit sample numbers (e.g., BC01, BC21). Each sample has a corresponding &#34;GB&#34; code which correlates to the code assigned during specimen collection.</li>
	</ol>
	</li>
	<li>Obtain up to nine tissue cores using a 14 G core needle biopsy gun under ultrasound guidance, in an outpatient clinic, operating room, or other aseptic environment.
	<ol>
		<li>For each core, obtain a breast sample approximately 2 cm in length at the center of the tumor and 1 cm away from the tumor for adjacent normal tissue. Collect two types of specimens from each participant: tumor tissue and normal tissue.</li>
		<li>Hand each sample to the URA for placement into a petri dish containing phosphate-buffered saline (PBS) solution. 
		NOTE:&#160;In this study, core needle biopsies were performed only on patients with Stage III and IV breast cancer. For Stage III patients, core needle biopsies provided chemotherapy-na&#239;ve tumor samples. For Stage IV patients, core needle biopsies served as the primary tumor sample, as mastectomy was not performed. For patients with Stage I and II breast cancer, no core needle biopsies were performed. Instead, tumor and adjacent normal tissues were obtained from mastectomy specimens.</li>
	</ol>
	</li>
	<li>Cut the biopsy specimens in half to distribute evenly between the study and histopathological analysis.
	<ol>
		<li>For tumor tissue, obtain up to 9 cores per study patient using a 14-G needle.</li>
		<li>Separate the tumor cores obtained into 2 groups in the Petri dish: samples for RNA analysis (6 cores) and samples for biobanking (3 cores).</li>
		<li>Cut each core into 2 lengthwise, but in cases where it is difficult to do this, cut the cores into 2 crosswise. Use a sterile blade to cut the cores. Send half of the tissue core for RNA analysis or store for biobanking. Send the other half of the tissue core to Pathology for routine histopathological analysis.</li>
		<li>For normal tissue, obtain up to 3 cores per study patient using a 14 G needle. Use a different needle from the one used to obtain tumor tissues to avoid contamination. In instances where this is not possible, obtain normal breast tissues first before getting tumor tissues.</li>
		<li>Place each normal tissue obtained in a Petri dish similar to what was done with the tumor tissues, and cut the cores in half. Distribute the samples for the study and to the Pathology Department for the histopathological analysis.</li>
	</ol>
	</li>
	<li>After sample collection, distribute the samples among the tubes, following a manner and order of priority.
	<ol>
		<li>Place half of the cores in the designated 2&#160;mL cryovial pre-filled with 1.25 mL of RNA stabilization solution (all cores for RNA analysis placed together in 1 vial and all cores for biobanking in a separate vial, maintain samples in cold temperature at all times) and place the corresponding halves of these cores in ordinary specimen vial/tube and fixed with 10% neutral buffered formalin (10% NBF), for histopathological analysis. Ensure that the two corresponding half-groups, the one going to the designated center (e.g., samples sent for RNA analysis), and the corresponding Pathology specimen have the same specimen code.</li>
	</ol>
	</li>
	<li>Complete the surgical pathology forms. Together with the forms, submit the Pathology specimens fixed with formalin to Pathology for routine histopathology.</li>
	<li>Seal with parafilm the core needle biopsy samples soaked in tubes containing RNA stabilization solution (ideally 5:1 ratio of solution to tissue, so if 0.25 cm tissue, 1.25 mL of RNA stabilization solution).</li>
	<li>Store the samples at 4 &#176;C for 24 h, and then eventually transfer it in the ultra-low freezer, with a temperature of -80 &#176;C. 
	NOTE: A guide on storage will be discussed in Section 4 (Storage, packing and transport of specimens).</li>
</ol>
3. Breast mastectomy sample collection procedure
<ol>
	<li>Follow the pre-breast sample collection procedure in Section 1. 
	NOTE: Stage I, II, and III patients enrolled in the study will undergo mastectomy at the Operating Room (OR). For Stages I and II patients, mastectomy will be done upfront, while for Stage III patients, mastectomy will only be done upon completion of 8 cycles of neoadjuvant therapy. For stage 4, no mastectomy samples are collected. See Figure 3 for the detailed breast mastectomy sample collection protocol showing the distribution of samples per procedure.</li>
	<li>Coordinate the schedule with the collaborators and the Pathology department. Do this at least 2 days prior to the target date of the procedure. In case of changes to the set schedule, inform the concerned personnel right away to avoid any conflicts in the schedule.</li>
	<li>Pre-label the tubes before specimen collection as GB, meaning Genomics&#160;Breast (the study the specimen is under), xxx which is the participant number and can range from 001 to 100, or more, and the letters E and F. The following are the letter codes to be used in labeling the tubes: 
	E - means mastectomy, tumor tissue, for sending to PGC, IB, and for biobanking 
	&#8203;F - means mastectomy, normal tissue
	<ol>
		<li>Assign the samples submitted for sequencing with the laboratory&#39;s label: &#34;BC&#34; and two digit sample number (e.g., BC01, BC21). Each sample has a corresponding &#34;GB&#34; code which correlates to the code assigned during specimen collection.</li>
	</ol>
	</li>
	<li>Fill out the surgical pathology forms during the surgery, while waiting for the specimen. Send updates to the pathologist-in-charge for them to make any necessary preparations for the specimen collection.</li>
	<li>Place the specimen in a clean plastic/specimen bag right after removal and documentation of the breast specimen. Ensure the mastectomy specimen is immediately brought to the Pathology department for grossing to minimize the cold ischemic time. Do not place the specimen in formalin upon submission. 
	NOTE: Sample action photos during mastectomy are shown in Figure 4 (Representative images of sample collection during mastectomy procedure).</li>
	<li>Obtain two types of samples from each specimen upon grossing: tumor tissue and normal tissue.
	<ol>
		<li>Tumor tissue
		<ol>
			<li>Obtain a minimum of one block (preferably more) measuring 1 cm &#215; 1 cm&#160;&#215; 1 cm of tumor tissue per specimen.</li>
			<li>Cut the obtained tissue block further into two parts, with each half block measuring 1 cm&#160;&#215; 0.5 cm&#160;&#215; 0.5 cm. Hand over half of the tissue block to the URA for biobanking and analysis, and then fix the other half in formalin for routine histopathology.</li>
			<li>Evenly trisect the half block of fresh tissue. This will be intended for RNA sequencing, biobanking, and organoid culture.</li>
			<li>For RNA sequencing: Immediately place in pre-chilled, pre-labeled 5 mL cryovials,&#160;pre-filled with 2.5 mL&#160;RNA stabilization solution (not exceeding 30 min, must be kept cold at all times).</li>
			<li>For biobanking: Immediately place in pre-chilled, pre-labeled, and pre-filled 5 mL cryovials with 2.5 mL RNA stabilization solution (not exceeding 30 min, must be kept cold at all times).</li>
			<li>For organoid culture: Immediately place in pre-chilled, pre-labeled, and pre-filled 15 mL conical vials with 5 mL of tissue storage solution and 0.01 mL Primocin (not exceeding 30 min, must be kept cold at all times). Pool together in one conical tube one-third of all the tumor blocks obtained from different sections of the specimen.</li>
		</ol>
		</li>
		<li>Normal tissue
		<ol>
			<li>Obtain a minimum of one block (preferably more) measuring 1 cm&#160;&#215; 1 cm&#160;&#215; 1 cm of normal breast tissue per specimen.</li>
			<li>Cut the obtained tissue block further into two parts, with each half block measuring 1 cm &#215; 1 cm&#160;&#215;&#160;0.5 cm. Hand over half of the tissue block to the URA for biobanking and analysis, and then fix the other half in formalin for routine histopathology.</li>
			<li>Cut the tissue block equally into two for the study. These will be intended for RNA sequencing and biobanking.</li>
			<li>For RNA sequencing: Immediately place in pre-chilled, pre-labeled&#160;5 mL cryovials, pre-filled with 2.5 mL cryovials with RNA stabilization solution (not exceeding 30 min, maintain at cold temperature at all times).</li>
			<li>For biobanking, immediately place in pre-chilled, pre-labeled, and pre-filled 2.5 mL cryovials with RNA stabilization solution (not exceeding 30 min, maintain at cold temperature at all times). 
			NOTE: Tumor samples labeled &#34;E&#34; are typically obtained from three or more different sections of the specimen. To avoid confusion, tumor samples intended for RNA analysis and biobanking should be placed into separate tubes labeled as E1, E2, E3, etc., while pooled tumor samples intended for cell culture should be placed into tubes labeled simply as E. For samples labeled E1, E2, and E3, the relative position/location of each tissue sample with respect to the tumor (e.g., center, 10 o&#39;clock position) should be recorded.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Seal with parafilm the cryovials containing the samples obtained from the mastectomy.</li>
	<li>Store the cryovials in 4 &#176;C for 24 h, and then eventually transfer them to the ultra-low freezer, with a temperature of -80 &#176;C for long-term storage.</li>
	<li>Pack the conical tube containing the pooled tumor blocks and prepare it for transport. These tumor blocks will be used for cell culture into organoids.</li>
</ol>
4. Storage, packing, and transport of specimens
<ol>
	<li>Immediately seal with parafilm all cryovials containing the tumor and normal tissues and store these at 4 &#176;C for 24 h. After 24 h, transfer the tubes to -20 &#176;C for around 2-4 h and then eventually transfer them to -80 &#176;C indefinitely, for long-term storage until transport.</li>
	<li>Update the specimen tracker and database prior to transport of samples for RNA analysis, including the results of routine histopathology and tumor percentages, to ensure the identity of the sample.</li>
	<li>Accomplish a transportation manifest for each sample, prior to transport. Ensure that the packing process is quick and the tubes containing the samples are not left at room temperature (RT) for a prolonged period.
	<ol>
		<li>Seal all cryovial caps with parafilm to prevent leakage.</li>
		<li>Place all the tubes in a test tube rack.</li>
		<li>Set the temperature logger and place it over the rack alongside the tubes for transport.</li>
		<li>Wrap the tubes with absorbent material, then with bubble wrap, and place the items inside the resealable bag. Ensure that the temperature logger is recording temperature and that the tubes are intact and positioned upright before sealing the items inside the bag.</li>
		<li>Place the gel packs on the bottom of the polystyrene shipping box, then set the resealable bag containing the tubes on top of the gel packs. Put another layer of gel packs on top of the bag. Make sure the tubes are sandwiched between gel packs to ensure the specimens will be kept cold during transport.</li>
		<li>Close the polystyrene box and put it inside a cardboard shipping box. If there is no large cardboard box available, use a larger polystyrene box. Place the completed transportation manifest inside a ziplock bag and put it inside the box. Placement of the items inside the box is shown in Figure 5.</li>
		<li>Seal the cardboard box and place the appropriate shipping label outside the box.</li>
	</ol>
	</li>
	<li>Inform the recipient of the specimen collection schedule and when the target sending of samples will be.
	<ol>
		<li>For organoid culture, only tumor tissues derived from mastectomies are sent and utilized. Ensure these are delivered fresh, on wet ice, and within 24 h from specimen collection. Once the samples are packed and the box is sealed, quickly book a courier to transport them. Ensure that the boxes will not be left in high-temperature areas for prolonged periods, as a severe temperature drop or rise can compromise the viability of the samples.</li>
		<li>Prior to handing off to the courier, take note of the number of vials/tubes shipped and the time the courier left the Biobank. Upon arrival of the package, ensure that the recipient takes note of the following: Time of arrival and receipt at the designated center, temperature at arrival, number of vials/tubes received, and any compromised specimen</li>
		<li>For RNA analysis, check if the samples to be delivered have a corresponding histopathology result and tumor percentages from the Surgical Pathology Division, prior to sending samples for RNA analysis. Identify and select the tissue block with the highest tumor content for each patient to be submitted for RNA extraction. Transport samples only those with tumor percentages.</li>
		<li>Send the samples in groups of no more than 40 to facilitate batch processing. Choose any combination of tumor tissue from core needle biopsy or mastectomy and normal tissue from mastectomy. Review the following conditions if normal tissue from core needle biopsy is to be transported: 
		-Enrolled as Stage 3, but histopathology result shows Stage 4 
		-Enrolled as Stage 3, but histopathology result shows loco-regional progression of disease.</li>
		<li>Ensure that all samples are transported on wet ice. Similar to the protocol being followed when sending samples for 3D cell culture, once the specimens are packed and the box is sealed, promptly book a courier for transport. Avoid leaving the boxes in high-temperature areas for prolonged periods, as significant temperature fluctuations can compromise the viability of the samples.</li>
		<li>Prior to handing off to the courier, take note of the number of vials/tubes shipped and the time the courier left the Biobank. Note the following upon arrival of the package: time of arrival and receipt at the designated center, temperature at arrival, number of vials/tubes received, and any compromised specimen (if there is any).</li>
	</ol>
	</li>
	<li>Update the database of samples sent and input all necessary information needed prior to further processing of samples. Monitor and assess the database once a week.</li>
</ol>

<ol><li>Wu, T., Lee, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Promoting+breast+cancer+awareness+and+screening+practices+for+early+detection+in+low-resource+settings%5BTitle%5D)+AND+%22Eur+J+Breast+Health%22%5BJournal%5D)">Promoting breast cancer awareness and screening practices for early detection in low-resource settings.</a> Eur J Breast Health. 15 (1), 18-25 (2018).</li>
<li>De Leon Matsuda, M. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((BRCA1+and+BRCA2+mutations+among+breast+cancer+patients+from+the+Philippines%5BTitle%5D)+AND+%22Int+J+Cancer%22%5BJournal%5D)">BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines.</a> Int J Cancer. 98 (4), 596-603 (2002).</li>
<li>Ngelangel, C. A., Wang, E. H. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+and+the+Philippine+Cancer+Control+Program%5BTitle%5D)+AND+%22Jpn.+J+Clin+Oncol%22%5BJournal%5D)">Cancer and the Philippine Cancer Control Program.</a> Jpn. J Clin Oncol. 32 Suppl, S52-S61 (2002).</li>
<li>Lee, S., Jung, P. E., Lee, Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Publicly-funded+biobanks+and+networks+in+East+Asia%5BTitle%5D)+AND+%22SpringerPlus%22%5BJournal%5D)">Publicly-funded biobanks and networks in East Asia.</a> SpringerPlus. 5 (1), 1080(2016).</li>
<li>Murtagh, M. J., Demir, I., Harris, J. R., Burton, P. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Realizing+the+promise+of+population+biobanks%3A+a+new+model+for+translation%5BTitle%5D)+AND+%22Hum+Genet%22%5BJournal%5D)">Realizing the promise of population biobanks: a new model for translation.</a> Hum Genet. 130, 333-345 (2011).</li>
<li>Coppola, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biobanking+in+health+care%3A+evolution+and+future+directions%5BTitle%5D)+AND+%22J+Transl+Med%22%5BJournal%5D)">Biobanking in health care: evolution and future directions.</a> J Transl Med. 17 (1), 172(2019).</li>
<li>Sajo, M. E. J. V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+pilot+cancer-phenome+biobanking+system+in+a+low-resource+Southeast+Asian+setting%3A+The+Philippine+general+hospital+biobank+experience%5BTitle%5D)+AND+%22Biopreserv+Biobank%22%5BJournal%5D)">A pilot cancer-phenome biobanking system in a low-resource Southeast Asian setting: The Philippine general hospital biobank experience.</a> Biopreserv Biobank. 18 (3), 180-188 (2020).</li>
<li>Considerations for RNA Seq Read Length and Coverage. , Illumina Knowledge. 
 <a target="_blank" href="https://knowledge.illumina.com/library-preparation/rna-library-prep/library-preparation-rna-library-prep-reference_material-list/000001243 ">https://knowledge.illumina.com/library-preparation/rna-library-prep/library-preparation-rna-library-prep-reference_material-list/000001243 </a> (2024).</li>
<li>Evidence-based clinical practice guidelines for early breast cancer. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=%22Phil+J+Surg+Specialties%22">Phil J Surg Specialties</a>. 68 (2), 41-74 (2013).</li>
<li>Al-Ismaeel, A. H., Nugud, A., Nugud, A., Nugud, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Ultrasonography-guided+core+needle+biopsy+diagnostic+value+in+breast+lump+assessment%3A+An+experience+from+the+Middle+East%5BTitle%5D)+AND+%22J+Diagn+Med+Sonogr%22%5BJournal%5D)">Ultrasonography-guided core needle biopsy diagnostic value in breast lump assessment: An experience from the Middle East.</a> J Diagn Med Sonogr. 37 (1), 5-11 (2021).</li>
<li>Poontananggoon, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Accuracy+of+ultrasound-guided+core-needle+biopsy+on+non-palpable+breast+masses%5BTitle%5D)+AND+%22Srinagarind+Med+J%22%5BJournal%5D)">Accuracy of ultrasound-guided core-needle biopsy on non-palpable breast masses.</a> Srinagarind Med J. 35 (2), 125-128 (2020).</li>
<li>Finak, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Gene+expression+signatures+of+morphologically+normal+breast+tissue+identify+basal-like+tumors%5BTitle%5D)+AND+%22Breast+Cancer+Res%22%5BJournal%5D)">Gene expression signatures of morphologically normal breast tissue identify basal-like tumors.</a> Breast Cancer Res. 8 (5), R58(2006).</li>
<li>Johnson, K. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Normal+breast+tissue+DNA+methylation+differences+at+regulatory+elements+are+associated+with+the+cancer+risk+factor+age%5BTitle%5D)+AND+%22Breast+Cancer+Res%22%5BJournal%5D)">Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.</a> Breast Cancer Res. 19 (1), 81(2017).</li>
<li>Smits, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+estimation+of+tumor+cell+percentage+for+molecular+testing+by+pathologists+is+not+accurate%5BTitle%5D)+AND+%22Mod+Pathol%22%5BJournal%5D)">The estimation of tumor cell percentage for molecular testing by pathologists is not accurate.</a> Mod Pathol. 27, 168-174 (2014).</li>
<li>Busheri, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Breast+cancer+biobank+from+a+single+institutional+cohort+in+an+urban+setting+in+India%3A+Tumor+characteristics+and+survival+outcomes%5BTitle%5D)+AND+%22Cancer+Treat+Res+Commun%22%5BJournal%5D)">Breast cancer biobank from a single institutional cohort in an urban setting in India: Tumor characteristics and survival outcomes.</a> Cancer Treat Res Commun. 28, 100409(2021).</li>
<li>Pekar, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Biobanking+multifocal+breast+carcinomas%3A+sample+adequacy+with+regard+to+histology+and+DNA+content%5BTitle%5D)+AND+%22Histopathology%22%5BJournal%5D)">Biobanking multifocal breast carcinomas: sample adequacy with regard to histology and DNA content.</a> Histopathology. 68, 411-421 (2016).</li>
</ol>

The authors do not have any conflict of interest, whether financial, personal, or institutional, to disclose.

The successful implementation of this protocol relies not only on technical precision but also on&#160;the coordination of clinical and research teams to ensure consistent sample quality and data integrity. This protocol incorporates several key procedures designed to maximize diagnostic accuracy and generate high-quality biospecimens suitable for downstream molecular analyses. Key steps include ultrasound-guided core needle biopsy for obtaining both normal and tumor breast tissue, data collection on treatment response, ...

Breast cancer stands as the most prevalent form of cancer among Filipino women. In Asia, the Philippines exhibits one of the highest breast cancer mortality rates and lowest mortality-to-incidence ratio1. The rates may have been greatly affected by the absence of screening programs and timely and effective treatment for breast cancer. In the country, breast cancer is typically diagnosed in later stages since most cancer patients only seek consultation at advanced cancer stages. In the Philippines, where a high incidence rate of breast cancer is observed, 53% of breast cancer cases were diagnosed in Stages III and IV, and only 2-3% were diagnosed in Stage I1,2,3. Aside from promoting screening uptake and patient education on breast cancer, breast cancer-related research and development should be explored further to decrease breast cancer incidence in the country.
The establishment of biobanks across the globe allowed the acceleration of medical advances. Biobanks are used for the storage and preservation of scientifically valuable biological specimens for future research and development4. Since then, biobanks have been used for translational research5 and improving personalized medical approaches6. In Asia, biobanks are mostly concentrated in East Asia, especially in China, Japan, and Korea4. In low- to middle-income countries in Asia, such as the Philippines, the concept of biobanking is still emerging. Biobanks in the Philippines are mostly owned by private healthcare institutions, where the health and exposure status of the broader Philippine demographics may not be well-represented.
The establishment of the cancer biobank at the University of the Philippines Manila (UPM) Philippine General Hospital (PGH) has proven the feasibility of establishing a government-supported cancer biobank that can advance cancer-related studies in the Philippines7. Building upon this foundation through a collaborative effort that bridges medical expertise, research innovation, and healthcare policy, we endeavor to create a positive shift in the landscape of breast cancer care and research in the Philippines. With that, there is an imperative need to have a cancer phenome biobanking workflow and an expanded approach that streamlines the collection of extensive and stratified patient-specific data on a national scale. This study describes the protocol for breast biopsy and mastectomy sample collection procedures, focusing on their integration into the biobanking framework. Anticipating not only advancing our understanding of breast cancer pathogenesis within the context of the Filipino population but also facilitating the development of precision treatments that align with the unique genetic, environmental, and clinical attributes of affected individuals.

<table><tbody><tr><td>37% Formalin solution</td><td>PHILUSA Corporation</td><td>N/A</td><td>Used as a preservative of tissues for histopathological analysis</td></tr><tr><td>70% Isopropyl alcohol</td><td>Green Cross Inc.</td><td>N/A</td><td>Used as a disinfectant</td></tr><tr><td>Barcode printer</td><td>Zebra</td><td>GC420t</td><td>For printing of barcode labels to be used in labelling tubes containing the samples</td></tr><tr><td>Bleach</td><td>Green Cross Inc.</td><td>N/A</td><td>Used as a disinfectant; for decontamination of surgical tools</td></tr><tr><td>Blue ice packs</td><td>Rubbermaid</td><td>1002</td><td>For keeping samples at low temperatures during transport</td></tr><tr><td>Core needle biopsy 14-G needle</td><td>Bard</td><td>MN1410</td><td>An invasive tubular surgical instrument designed to be connected to a biopsy gun handpiece for the automatic extraction of a small tissue sample from an anatomical structure (a biopsy), while causing minimal surrounding tissue damage, for tissue pathological examination/testing.</td></tr><tr><td>Core needle breast biopsy gun</td><td>Bard</td><td>MG1522</td><td>Reusable core biopsy instrument used in collecting tissue samples during core needle biopsy</td></tr><tr><td>Disposable Petri Dish 90 mm x 15 mm</td><td>Phoenix Biomedical Products</td><td>LOT: 20220206</td><td>Used in core needle biopsy specimen collection when submerging tissues in PBS</td></tr><tr><td>Dulbecco&#039;s phosphate-buffered saline (PBS)</td><td>Thermo Fisher Scientific</td><td>21600010</td><td>A balanced salt solution used for a variety of cell culture applications, such as washing cells before dissociation, transporting cells or tissue, diluting cells for counting, and preparing reagents.&amp;nbsp;</td></tr><tr><td>Forceps</td><td>Local Supplier</td><td>N/A</td><td></td></tr><tr><td>Kimtech Science KimWipes Delicate Task Wipers</td><td>Kimberly Clark Professional</td><td>KC34120</td><td>4.3 x 8.4 in. (11.0 cm x 21.3 cm); 1-ply 280 Count; for cleaning surfaces, parts, instruments, and medical offices, these wipes easily clean liquids, dust and small particles.</td></tr><tr><td>MACS Tissue storage solution</td><td>Miltenyi Biotec</td><td>130-100-008</td><td>Storage solution used to allow an optimized storage of fresh organ and tissue samples</td></tr><tr><td>Micropipette</td><td>Shanghai Lichen Instrument Technology Co., Ltd.</td><td>STEM-GC-3197-Y</td><td>for pipetting/transferring liquids in small volumes</td></tr><tr><td>Micropipette tips</td><td>Tarsons</td><td>521100</td><td>for pipetting/transferring liquids in small volumes</td></tr><tr><td>Parafilm</td><td>Parafilm M</td><td>5259-04LC PM996</td><td>For airtight and moisture-proof sealing of tubes to prevent leaks</td></tr><tr><td>Primocin 250 mg (5 x 1 mL)</td><td>InvivoGen</td><td>ant-pm-05</td><td>Used to protect tissues from microbial contamination</td></tr><tr><td>Refrigerator (4 &amp;deg;C)</td><td>LG</td><td>Model: GR-Y331SLZB</td><td>For storage of tissue samples and reagents</td></tr><tr><td>RNAlater solution</td><td>Thermo Fisher Scientific</td><td>AM7021</td><td>RNA stabilization solution used in the storage and biobanking of tissues</td></tr><tr><td>Sterile 15 mL conical tube&amp;nbsp;</td><td>Thermo Scientific</td><td>339650</td><td>Used to make aliquots of reagents/media used in tissue storage</td></tr><tr><td>Sterile 5 mL Cryovials</td><td>Thermo Scientific</td><td>5000-1020</td><td>Used to make aliquots of reagents/media used in tissue storage</td></tr><tr><td>Sterile scalpel blade (#11)</td><td>Surgitech</td><td>N/A</td><td>For cutting tumor and normal breast tissues</td></tr><tr><td>Surgical scissors (18.5 cm 7 &amp;frac14;&quot; str)</td><td>Olten Instruments</td><td>BO-0125</td><td>For cutting tumor and normal breast tissues</td></tr><tr><td>Temperature logger</td><td>Extech Instruments</td><td>42280</td><td>For recording temperature and humidity during transport of samples</td></tr><tr><td>Tissue ink</td><td>Epredia</td><td>3120123</td><td>For staining the margins of excised surgical specimens for histopathological analysis</td></tr><tr><td>Ultra-low freezer</td><td>Haier Biomedical</td><td>DW-86L579</td><td>For indefinite storage of tumor and normal breast tissues</td></tr><tr><td>Urine specimen container 60mL</td><td>Sure Guard</td><td>0016UCS06PC</td><td>For storage of tissues for histopathological analysis</td></tr><tr><td>Ziplock Bags</td><td>Reynolds Consumer Products LLC</td><td></td><td>Used in packing the samples for transport</td></tr></tbody></table>

optimization of breast biopsy and mastectomy sample collection procedures for biobanking, personalized medicine, and research applications

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Breast cancer is the most prevalent cancer affecting women, particularly in Asia, with the highest incidence in the Philippines. Despite ongoing efforts, the understanding of breast cancer biology remains inadequate, compounded by the lack of effective screening programs and timely treatments. Addressing these issues, biobanks and other repositories for biological specimens have gained global momentum. The University of the Philippines- Philippine General Hospital (UP-PGH) has established a cancer biobank, demonstrating the viability of a government-supported initiative for cancer research in the Philippines. The study involves a prospective observation of 100 Filipino breast cancer patients at various disease stages, leveraging the expertise of UP-PGH, Philippine Genome Center (PGC), and University of the Philippines Diliman - Institute of Biology (UPD-IB). It integrates the collection, processing, and storage of biospecimens alongside comprehensive patient data. Procedures include RNA extraction, library preparation, and sequencing. Additionally, a subset of patients participates in an in vitro three-dimensional (3D) cell culture experiment for chemotherapy pre-screening. The aggregated data aims to uncover therapeutic strategies that can lead to personalized treatments where standard clinical approaches are inadequate. Key techniques include ultrasound-guided core needle biopsy, meticulous normal breast tissue collection, and precise tumor percentage determination to ensure high-quality RNA extraction, sequencing, and 3D cell culture. The study also addresses challenges encountered in prior biobanking endeavors. Ultimately, this research aims to contribute significantly to breast cancer research, positioning itself as a model for collaborative research, biobank establishment, and the advancement of precision medicine in developing countries, such as the Philippines.

For the collection of samples during core needle biopsy, doing the procedure under ultrasound guidance had a huge impact on patient convenience and efficiency of workflow, as well as on the RNA integrity of the samples. If this is not done, the expected results might not be obtained, and patients must go back to the clinics to repeat the procedure, therefore prolonging sample collection and processing.
In addition to that, identification of tumor percentages per sample, which was done by the p...

This article presents a detailed protocol for collecting breast cancer samples, designed to optimize their utility for biobanking, personalized medicine, and other research applications. The workflow for sample collection, including breast biopsy and mastectomy procedures, is described in detail, focusing on minimizing tissue damage and maximizing sample quality.

Breast cancer is the most prevalent cancer affecting women, particularly in Asia, with the highest incidence in the Philippines. Despite ongoing efforts, ...

The scope aims to improve cancer sample collection for biobanking so that it will enable better personalized treatment through high quality RNA sequencing and organoid culture from Filipino breast cancer tissues. Recent advances include using patient-derived organoids and RNA sequencing to predict treatment response in breast cancer in a recent paper, particularly for cases with lymphovascular invasion linked to drug resistance. We use ultrasound guided biopsies, RNA sequencing tumor percentage estimation and 3D organoid cultures to analyze breast cancer tissues precisely.Main challenges include obtaining high quality RNA from small biopsy samples, quality issues for organoid preservation. So after starting with breast cancer, we'll explore further gene expression in a larger Filipino cohort and use organoids to test therapies for the following:thyroid, ovarian, pancreatic, and rare cancers like phyllodes tumors. To begin, set up a 14 gauge core needle biopsy gun under ultrasound guidance in an outpatient clinic, operating room, or other aseptic environment.For each core, collect a breast sample approximately two centimeters in length from the center of the tumor and one centimeter away for adjacent normal tissue. Collect two types of specimens, normal tissue and tumor tissue, from each patient. Hand each sample to the research assistant for placement into a Petri dish containing PBS solution.Sort the nine tumor tissue samples into six cores for RNA analysis and three cores for biobanking. Cut each core lengthwise or crosswise using a sterile blade. Place the three normal tissue cores in Petri dishes.Cut the cores in half and allocate them for analysis. Distribute samples among the tubes according to priority. Place half of the cores into designated two milliliter cryo vials with 1.25 milliliters of RNA stabilization solution.Fix the other halves in specimen vials containing 10%neutral buffered formalin. Complete and submit the surgical pathology forms with the fixed samples to the pathology department. After mastectomy, place the sample into a clean specimen bag after documentation and transport immediately to the Department of Laboratories pathology without formalin to reduce cold ischemic time.Obtain a minimum one cubic centimeter tumor tissue block during grossing and cut into two halves. Evenly trisect the fresh half block for RNA sequencing, biobanking and organoid culture. Immediately place the tissue for RNA sequencing in five milliliter pre-chilled and pre-labeled cryo vials pre-filled with 2.5 milliliters of RNA stabilization solution.For biobanking, use five milliliter cryo vials with the same solution. For organoid culture, use 15 milliliter conical vials, pre-filled with five milliliters of tissue storage solution and 0.01 milliliters of primocin. Pull one third of all tumor blocks into one conical tube.Obtain a minimum of one cubic centimeter normal tissue block and slice it in half for RNA biobanking and routine histopathology. Transfer the tissue block into five milliliter pre-chilled and pre-labeled cryo vials pre-filled with 2.5 milliliters of RNA stabilization solution for RNA sequencing and biobanking. Then seal all cryo vials with parafilm.Store at four degrees Celsius for 24 hours. Then transfer to minus 20 degrees Celsius for two to four hours. And finally, store at minus 80 degrees Celsius.Seal the cryo vial caps with parafilm. Place the sealed cryo vials in a test tube rack and cover with absorbent and bubble wrap. Place the wrapped rack in a resealable bag with a temperature logger.Position gel packs on the bottom of a polystyrene box. Then place the bag over the gel packs. Put another layer of gel packs on top of the bag.Make sure the tubes are sandwiched between gel packs to ensure the specimens will be kept cold during transport. Put the closed polystyrene box into a cardboard shipping box and include the manifest in a Ziploc bag. Seal and label the box for shipping.Before courier handoff, note the number of vials and the departure time from the biobank. Two samples with varying RIN values and concentration failed in the library preparation step during sequencing and were excluded in the final analysis. All samples had great sequencing quality scores where more than 90%of base calls had an accuracy of at least 99.9%Bright-field imaging showed successful organoid formation from stage three breast cancer mastectomy tissues after neoadjuvant therapy with abundant spheroid-like structures visible at low and high magnification.

optimization-breast-biopsy-mastectomy-sample-collection-procedures

Research

JoVE Journal

Medicine

This video demonstrates an MRI data-based technique to target specific tumor-containing regions in prostate tissue for sampling. The collected biopsy specimens can be either stored for biobanking purposes or used for subsequent downstream analysis.

Sampling Prostate Cancer Tissue for Biobanking: An MRI-guided Targeted Technique to Remove Biopsy Punches from Fresh Tumor Tissue

Cutaneous tumors are often discarded following Mohs micrographic surgery. A protocol is described here that enables clinical support staff to effectively process and store cutaneous tumor (e.g., squamous cell carcinoma, basal cell carcinoma, and melanoma) samples for downstream laboratory applications without interfering with clinical operations.

Establishment of a Clinic-based Biorepository

Nucleic acid degradation in archival tissue, tumor heterogeneity, and a lack of fresh frozen tissue specimens can negatively impact cancer diagnostic services in pathology laboratories worldwide. This manuscript describes the optimization of a panel of biomarkers using a multiplex magnetic bead assay to classify breast cancers.

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

This method involves utilization of clinical diagnostic data for prostate cancer patients in order to guide sampling procedures, when biobanking tissue following radical prostatectomy. This overcomes issues with previously published methods around efficiency and availability of fresh tissue for a wider range of downstream applications.

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

In the following work, we describe the consecutive steps necessary for the establishment of a large biobank of colorectal and pancreatic cancer.

Creation and Maintenance of a Living Biobank - How We Do It

Biobanks are crucial resources for biomedical research and the Biobank for Translational and Digital Medicine Unit at the European Institute of Oncology is a model in this field. Here, we provide a detailed description of biobanks' standard operating procedures for the management of different types of human biological samples.

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

The liquid biopsy has revolutionized our approach to oncology translational studies, with sample collection, quality, and storage being crucial steps for its successful clinical application. Here we describe a standardized and validated protocol for downstream circulating-free DNA applications that can be applied in most translational research laboratories.

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

This protocol describes a method for facilitating the collection of samples from radical prostatectomy specimens. The goal is to map, characterize, and micro-macro dissect tissue samples from the specimens based on anatomopathological criteria before storing them in a Biobank.

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle.  Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.

Bronchial Thermoplasty:  A Novel Therapeutic Approach to Severe Asthma

In the following sections, we outline procedures for the preparation of alginate microspheres for use in biomedical applications. We specifically illustrate a technique for creating multilayered alginate microspheres for the dual purpose of cell and protein encapsulation as a potential treatment for type 1 diabetes.

Generation of Alginate Microspheres for Biomedical Applications

Learn optimized breast biopsy and mastectomy sample collection for biobanking and personalized medicine using ultrasound-guided techniques. This protocol enables high-quality RNA sequencing and organoid culture for cancer research.

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications (Video) | JoVE Journal

Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications

Explore More Videos